XIIDRA

bausch & lomb inc🇨🇦 Health Canada

Approval Id: a1c0df3bde27fbca
Drug Approval Canada Name: XIIDRA
Product Name: XIIDRA
Status: Marketed
Status Date: 2024-08-20
Original Market Date: 2018-02-12
Din: 02471027
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Ophthalmic
Schedule: Prescription
Ahfs: 52:08.00
Atc Original: S01XA25 LIFITEGRAST
Atc Name: s 01 xa 25
Aig Number: 0159830001
Company Name: bausch & lomb inc
Company Address: 1400 N Goodman Street, Rochester, New York, United States, 14609

LIFITEGRAST

5 % / W/V

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

a1c0df3bde27fbca

Type

Standard